Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy

NCT ID: NCT00933816

Last Updated: 2010-11-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2010-10-31

Brief Summary

The purpose of this study is to determine the recommended dose of the combination therapy of sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients with advanced hepatocellular carcinoma (Phase I), and to evaluate the efficacy of this combination therapy in the recommended dose (Phase II).

Detailed Description

In Phase I, there will be 9 to 18 patients enrolled. Cohorts of 3 to 6 patients will receive escalated dose of cisplatin and fluorouracil until the MTD is reached. There will be no intra-patient dose escalation. Sorafenib will be administered orally at a dose of 400mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued. At the end of each cycle, adverse effect will be evaluated and dose escalation will be determined. In Phase II, there will be 28 patients enrolled. Time to progression of this combination therapy at the recommended dose will be evaluated.

Conditions

Hepatocellular Carcinoma

Keywords

sorafenib; intraarterial infusion chemotherapy; Low dose FP; cisplatin; fluorouracil

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib with Low-dose FP

Group Type: EXPERIMENTAL

sorafenib, cisplatin, fluorouracil

Intervention Type: DRUG

Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.

Interventions

sorafenib, cisplatin, fluorouracil

Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.

Intervention Type: DRUG

Other Intervention Names

sorafenib with hepatic arterial infusion of low dose FP

Eligibility Criteria

Inclusion Criteria

1. 20 Years and older.

2. Life expectancy of at least 12 weeks at the pre-treatment evaluation.

3. Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or typical findings by dynamic CT or CT during hepatic arteriography/arterioportography.

4. Not suitable for resection or local ablation therapy or transcatheter arterial chemoembolization.

5. One treatment of hepatic arterial infusion chemotherapy without implanted catheter system is allowed.

6. ECOG Performance status of 0 or 1.

7. Cirrhotic status of Child-Pugh class A or B.

8. Adequate bone marrow, liver and renal function, as assessed by the following laboratory requirements:

• Hemoglobin 8.5 g/dl
• Granulocytes 1500/μL
• Platelet count 50,000 /μL
• PT-INR 2.3 or PT 6 seconds above control
• Total serum bilirubin 2 mg/dl
• AST(SGOT) and ALT(SGPT) 5 × upper limit of normal
• Serum creatinine 1.5 × upper limit of normal
• Amylase 5 × upper limit of normal

9. Written Informed Consent must be obtained.

Exclusion Criteria

1. Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1], early gastric cancer, or other malignancies curatively treated > 3 years prior to entry

2. Renal failure

3. Any heart disease as follows

• Congestive heart failure defined as NYHA class III or IV
• Active coronary artery disease or ischemic heart disease such as cardiac infarction within 6 months prior to screening
• Serious cardiac arrhythmia
• Serious hypertension

4. Active clinically serious infections.

5. Active chicken pox.

6. Auditory disorder.

7. Known history of HIV infection.

8. Known metastatic or meningeal tumors.

9. Extrahepatic tumor spread.

10. History of seizure disorder.

11. Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry.

12. Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization).

13. Any history of treatment as follows:

• Treatment with the agent which induces CYP3A4
• Surgical procedure within 4 weeks prior to start of study drug
• History of organ allograft

14. Patients unable to swallow oral medications.

15. Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics.

16. Medication that may affect to the absorption of drug or pharmacokinetics.

17. Any disease or disorder that may affect the evaluation of study drug.

18. Entry to the other clinical trial within 4 weeks prior to entry to this study.

19. Pregnant or breast-feeding patients.

20. Known allergy to the investigational agent or any agent given in association with this trial.

21. Substance abuse, medical, psychological or social conditions that, in the judgment of the investigator, is likely to interfere with the patient's participation in the study or evaluation of the stuy results.

22. Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kindai University

OTHER

Sponsor Role: lead

Responsible Party

Japan Liver Oncology Group

Principal Investigators

Masatoshi Kudo

Role: PRINCIPAL_INVESTIGATOR

Kindai University

Locations

Kurume University Medical Center

Kurume, Fukuoka, Japan

Ogaki Municipal Hospital

Oogaki, Gifu, Japan

Kinki University School of Medicine

Ōsaka-sayama, Osaka, Japan

Countries

Japan

Other Identifiers

JLOG0901

Identifier Type: -

Identifier Source: org_study_id